Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12
The dire necessity for vaccine therapies became apparent with the COVID-19 pandemic that commenced in early 2020. Initially, former FDA Commissioner Hahn emphasized at the time of the pandemic there were no FDA-approved therapeutics or drugs to treat, cure or prevent COVID-19; however, there are now approved and authorized vaccines to combat this virus as well as treatments such as Remdesivir, an antiviral drug used for Ebola manufactured by Gilead Sciences, Inc. which was approved to treat COVID-19. Yet, the COVID-19 pandemic has proved tenacious with well over 825,000 deaths at the start of 2022 in the United States alone. Leading vaccines to prevent COVID-19 include emergency authorizations to Pfizer-BioNTech, Moderna and Johnson & Johnson.
Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
The United States Supreme Court pronouncement in Association for Molecular Pathology v. Myriad Genetics, hinged on whether naturally occurring human genes and/or isolating those genes from the body were a patentable invention. As the biosimilar market increases, issues concerning these products continue. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies. The United States Supreme Court settled the issue of notice of commercial marketing in Sandoz, Inc. v. Amgen Inc.
Biosimilars have become a multibillion-dollar market and in fact, one of the most expensive medicines in the world is a gene therapy drug approved whose cost is two million dollars. Congress passed the Biologics Price Competition and Innovation Act (BPCI or Biosimilars) Act, in Title VII of the 2010 Patient Protection and Affordable Care Act, Pub.L. 111-148, amended by the Health Care and Reconciliation Act of 2010 (Healthcare Reform Act). The BPCI Act established a 12-year exclusivity period before biosimilars can be approved for marketing in the United States. FDA approved the first biosimilar in 2015 and continues to do so throughout the ensuing years. In 2021, the Advancing Education on Biosimilars Act was passed whose aim is to improve federal initiatives to educate patients, doctors and caregivers about biosimilar drugs. Finally, FDA approved the first-ever interchangeable biosimilar in 2021.Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
"1140860288"
Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
The United States Supreme Court pronouncement in Association for Molecular Pathology v. Myriad Genetics, hinged on whether naturally occurring human genes and/or isolating those genes from the body were a patentable invention. As the biosimilar market increases, issues concerning these products continue. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies. The United States Supreme Court settled the issue of notice of commercial marketing in Sandoz, Inc. v. Amgen Inc.
Biosimilars have become a multibillion-dollar market and in fact, one of the most expensive medicines in the world is a gene therapy drug approved whose cost is two million dollars. Congress passed the Biologics Price Competition and Innovation Act (BPCI or Biosimilars) Act, in Title VII of the 2010 Patient Protection and Affordable Care Act, Pub.L. 111-148, amended by the Health Care and Reconciliation Act of 2010 (Healthcare Reform Act). The BPCI Act established a 12-year exclusivity period before biosimilars can be approved for marketing in the United States. FDA approved the first biosimilar in 2015 and continues to do so throughout the ensuing years. In 2021, the Advancing Education on Biosimilars Act was passed whose aim is to improve federal initiatives to educate patients, doctors and caregivers about biosimilar drugs. Finally, FDA approved the first-ever interchangeable biosimilar in 2021.Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12
The dire necessity for vaccine therapies became apparent with the COVID-19 pandemic that commenced in early 2020. Initially, former FDA Commissioner Hahn emphasized at the time of the pandemic there were no FDA-approved therapeutics or drugs to treat, cure or prevent COVID-19; however, there are now approved and authorized vaccines to combat this virus as well as treatments such as Remdesivir, an antiviral drug used for Ebola manufactured by Gilead Sciences, Inc. which was approved to treat COVID-19. Yet, the COVID-19 pandemic has proved tenacious with well over 825,000 deaths at the start of 2022 in the United States alone. Leading vaccines to prevent COVID-19 include emergency authorizations to Pfizer-BioNTech, Moderna and Johnson & Johnson.
Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
The United States Supreme Court pronouncement in Association for Molecular Pathology v. Myriad Genetics, hinged on whether naturally occurring human genes and/or isolating those genes from the body were a patentable invention. As the biosimilar market increases, issues concerning these products continue. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies. The United States Supreme Court settled the issue of notice of commercial marketing in Sandoz, Inc. v. Amgen Inc.
Biosimilars have become a multibillion-dollar market and in fact, one of the most expensive medicines in the world is a gene therapy drug approved whose cost is two million dollars. Congress passed the Biologics Price Competition and Innovation Act (BPCI or Biosimilars) Act, in Title VII of the 2010 Patient Protection and Affordable Care Act, Pub.L. 111-148, amended by the Health Care and Reconciliation Act of 2010 (Healthcare Reform Act). The BPCI Act established a 12-year exclusivity period before biosimilars can be approved for marketing in the United States. FDA approved the first biosimilar in 2015 and continues to do so throughout the ensuing years. In 2021, the Advancing Education on Biosimilars Act was passed whose aim is to improve federal initiatives to educate patients, doctors and caregivers about biosimilar drugs. Finally, FDA approved the first-ever interchangeable biosimilar in 2021.Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
The United States Supreme Court pronouncement in Association for Molecular Pathology v. Myriad Genetics, hinged on whether naturally occurring human genes and/or isolating those genes from the body were a patentable invention. As the biosimilar market increases, issues concerning these products continue. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies. The United States Supreme Court settled the issue of notice of commercial marketing in Sandoz, Inc. v. Amgen Inc.
Biosimilars have become a multibillion-dollar market and in fact, one of the most expensive medicines in the world is a gene therapy drug approved whose cost is two million dollars. Congress passed the Biologics Price Competition and Innovation Act (BPCI or Biosimilars) Act, in Title VII of the 2010 Patient Protection and Affordable Care Act, Pub.L. 111-148, amended by the Health Care and Reconciliation Act of 2010 (Healthcare Reform Act). The BPCI Act established a 12-year exclusivity period before biosimilars can be approved for marketing in the United States. FDA approved the first biosimilar in 2015 and continues to do so throughout the ensuing years. In 2021, the Advancing Education on Biosimilars Act was passed whose aim is to improve federal initiatives to educate patients, doctors and caregivers about biosimilar drugs. Finally, FDA approved the first-ever interchangeable biosimilar in 2021.Biologics including bioengineered or "biotech" therapies have proliferated the marketplace. The authority of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) stems from the Public Health Services Act (PHSA) and specific sections of the United States Food, Drug and Cosmetic Act (FDCA). Critical parameters in the regulation of these products remains science based to assure purity, potency, safety, efficacy, and availability. Biologics result from living sources such as humans, animals and microorganisms. They are unlike conventional drugs, which are chemically synthesized. Biologics involve complicated mixtures and are produced using biotechnology. Biologics include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or living entities such as cells and tissues. Generic versions of biotech drugs referred to as biosimilars or follow-on biologics present an interesting and complex issue for both industry and FDA. Increased competition, naming, high costs, transition to the PHSA licensing and attempts to stymie the market by brand companies.
42.89
In Stock
5
1
![Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12](http://img.images-bn.com/static/redesign/srcs/images/grey-box.png?v11.10.4)
Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12
![Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12](http://img.images-bn.com/static/redesign/srcs/images/grey-box.png?v11.10.4)
Biotechnology and Biologic Products Regulation: Food and Drug Law Book 6 of 12
eBook
$42.89
Related collections and offers
42.89
In Stock
Product Details
BN ID: | 2940160996899 |
---|---|
Publisher: | Forti Publications |
Publication date: | 01/08/2022 |
Series: | Food and Drug Law , #6 |
Sold by: | Barnes & Noble |
Format: | eBook |
File size: | 249 KB |
About the Author
From the B&N Reads Blog